Clinical Trial Update: Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating sublingual water-soluble CBD/PEA for diabetic peripheral neuropathic pain; status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathic Pain

Drugs mentioned

• CBD/PEA sublingual formulation (water-soluble CBD/PEA)

Snippet

Sponsor: Pure Green Pharmaceuticals Inc. | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 1, Phase 2 | Status: UNKNOWN